Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
---|---|---|---|---|---|---|
Adcirca | Tadalafil | Pulmonary arterial hypertension | List with clinical criteria and/or conditions | Complete | ||
Januvia | Sitagliptin phosphate | Diabetes mellitus (Type 2) | List with clinical criteria and/or conditions | Complete | ||
Janumet | Sitagliptin phosphate monohydrate / metformin hydrochloride | Diabetes mellitus (Type 2) | List with clinical criteria and/or conditions | Complete | ||
Isentress | Raltegravir | HIV (treatment naïve) | Do not list | Complete | ||
Onglyza | Saxagliptin | Diabetes mellitus (Type 2) | Do not list | Complete | ||
Orencia | Abatacept | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
Prezista | Darunavir | HIV infection (Pediatric) | List with clinical criteria and/or conditions | Complete | ||
Cimzia | Certolizumab pegol | Arthritis, rheumatoid | Do not list | Complete | ||
Multaq | Dronedarone hydrochloride | Atrial fibrillation | Do not list | Complete | ||
Nplate | Romiplostim | Chronic immune (idiopathic) thrombocytopenic purpura (ITP) | Do not list | Complete |